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Abstract
Background and Aims: Increasing evidence has suggested that hepatocellular carcinoma (HCC) might originate from a
distinct subpopulation called cancer stem cells (CSCs), which are responsible for the limited efficacy of conventional
therapies. We have previously demonstrated that granulin-epithelin precursor (GEP), a pluripotent growth factor, is
upregulated in HCC but not in the adjacent non-tumor, and that GEP is a potential therapeutic target for HCC. Here, we
characterized its expression pattern and stem cell properties in fetal and cancerous livers.
Methods: Protein expression of GEP in fetal and adult livers was examined in human and mouse models by
immunohistochemical staining and flow cytometry. Liver cancer cell lines, isolated based on their GEP and/or ATP-
dependent binding cassette (ABC) drug transporter ABCB5 expression, were evaluated for hepatic CSC properties in terms
of colony formation, chemoresistance and tumorigenicity.
Results: We demonstrated that GEP was a hepatic oncofetal protein that expressed in the fetal livers, but not in the normal
adult livers. Importantly, GEP+ fetal liver cells co-expressed the embryonic stem (ES) cell-related signaling molecules
including b-catenin, Oct4, Nanog, Sox2 and DLK1, and also hepatic CSC-markers CD133, EpCAM and ABCB5. Phenotypic
characterization in HCC clinical specimens and cell lines revealed that GEP+ cancer cells co-expressed these stem cell
markers similarly as the GEP+ fetal liver cells. Furthermore, GEP was shown to regulate the expression of ES cell-related
signaling molecules b-catenin, Oct4, Nanog, and Sox2. Isolated GEPhigh cancer cells showed enhanced colony formation
ability and chemoresistance when compared with the GEPlow counterparts. Co-expression of GEP and ABCB5 better defined
the CSC populations with enhanced tumorigenic ability in immunocompromised mice.
Conclusions: Our findings demonstrate that GEP is a hepatic oncofetal protein regulating ES cell-related signaling
molecules. Co-expression of GEP and ABCB5 further enriches a subpopulation with enhanced CSC properties. The current
data provide new insight into the therapeutic strategy.
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Introduction
Hepatocellular carcinoma (HCC), the third leading cause of
cancer mortality worldwide, is a highly malignant disease with no
effective treatment currently [1]. While the molecular mechanisms
of HCC pathogenesis remain largely unknown, HCC is considered
a heterogeneous disease due to its multiple molecular profiles and
varied clinical outcomes [2]. The heterogeneous nature of HCC
and the lack of appropriate biomarkers have impeded patient
prognosis and treatment.
For years, tumor cell heterogeneity has been explained by the
clonal evolution model [3]. However, recent evidence suggests that
tumors are hierarchically organized with a distinct subpopulation
called cancer stem cells (CSCs) lying at the apex of the hierarchy.
These cells are not only responsible for tumor initiation and
progression, but also endowed with stem cell properties, including
self-renewal, differentiation capacity and chemoresistance [4].
Although existing therapies can initially eliminate the bulk
population of tumor, the stem cell properties of CSCs enable
them to survive and repopulate the tumor, resulting in disease
relapse [5].
The concept of CSCs has been documented in diverse
malignancies including breast [6], colon [7] and liver cancers
[8,9]. Despite recent advances in hepatic CSC identification,
precise origin of these cells remains largely unknown. Tumor-
igenesis and embryogenesis are known to share many common
properties including cellular plasticity, dynamic cell motility [10]
and convergence of signaling pathways, suggesting a possible link
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between embryonic and cancer cells [11]. Interestingly, the
concept of CSC is notably similar to the ‘‘embryonal rest’’ theory,
which was proposed based on the histological similarities of
embryonic and cancerous tissues, suggesting that adult tissues
contain embryonic remnants that normally lie dormant, but can
be activated to become cancerous [12]. Therefore, identification of
key molecule that underlie the commonality of embryonic stem
(ES) cells and tumor cells might result in new therapeutic strategies
to suppress the malignant transformation of normal stem cells, or
eradicate the CSCs.
Granulin-epithelin precursor (GEP, also named progranulin,
proepithelin, acrogranin, or PC-derived growth factor) is a
pluripotent growth factor regulating fetal development [13], tissue
repair [14] and tumorigenesis in various cancers [15]. It was found
to regulate developmental events including cavitation in preim-
plantation mouse embryos [16] and male-specific brain differen-
tiation of the hypothalamus of neonatal rats [17]. Previously, we
have demonstrated GEP overexpression in the majority of human
HCC specimens [18,19] and its role in regulating HCC cell
proliferation, invasion and tumorigenicity [19]. Moreover, neu-
tralization of GEP could inhibit the growth of established HCC
[20]. Despite considerable interest in its dual roles in embryogen-
esis and tumorigenesis, information for its expression pattern and
biological functions in livers is still scarce.
In this study, we report for the first time that GEP is a hepatic
oncofetal protein that regulates the expression of stem cell-related
signalling molecules b-catenin, Oct4, Nanog and Sox2. Functional
studies confirmed that GEP-expressing cells possessed greater
ability in colony formation and chemoresistance. Furthermore,
cancer cells co-expressing GEP and ATP-dependent binding
cassette (ABC) B5 demonstrated enhanced tumorigenic ability in
immunocompromised mice. Our findings are crucial not only for
the understanding of fetal liver development, but also for
constructing specific therapies targeting GEP and ABCB5 to
eradicate the chemoresistant CSCs in HCC patients.
Materials and Methods
Cell assays
Human liver cancer cell lines, Hep3B and HepG2, were
purchased from American Type Culture Collection (Manassas,
VA) and cultured as previously described [19,20]; while Huh7 was
purchased from Health Science Research Resources Bank (Osaka,
Japan) and maintained in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine
serum (Invitrogen, Carlsbad, CA). Stable transfectants for GEP
overexpression and suppression have been described [19]. GEP
blockage in Hep3B was performed by incubating the cells with or
without 50 mg/ml anti-GEP monoclonal antibody A23 (home-
made, previously described [20] or mouse IgG isotype control
antibody (Sigma-Aldrich, St. Louis, MO) for 24 h.
Clinical specimens
The study protocol was approved by the Institutional Review
Board of the University of Hong Kong/Hospital Authority Hong
KongWest Cluster (HKU/HAHKW IRB). Six patients underwent
curative partial hepatectomy or liver transplantation for HCC at
Queen Mary Hospital, Hong Kong, were recruited with written
informed consent to the study. The patients had been diagnosed
with primary HCC and confirmed by pathological examinations.
The age of the patients ranged from 42 to 67 years, with a median
age of 60 years. There were 4 men and 2 women, and all were
hepatitis B virus carriers. The size of the tumors ranged from 3.5 to
19.5 cm, with a median size of 8.3 cm. Notably, each specimen has
limited number of cells (small research specimen to ensure no
interference to pathological examination) and therefore not
sufficient for the complete panel of stem cell marker expression
analysis. The expression data of each marker presented the average
data from at least four samples. The normal liver specimen was
obtained from organ donor during transplantation operation, and
the donor had no underlying liver disease and was negative in the
hepatitis B serology test. The fetal liver specimen was obtained from
retrieval of archived formalin fixed paraffin embedded tissue block
taken during routine pathological examination of the abortus after
spontaneous miscarriage at 10 weeks 6 days. Ethics approval for the
use of archived fetal tissues identified from a computer database has
been obtained from the Institutional Review Board of the University
of Hong Kong/Hospital Authority Hong Kong West Cluster
(HKU/HA HKW IRB).
Mouse specimens
Livers from adult, neonatal and fetal ICR mice were collected
and the study protocol was approved by the Committee on the
Use of Live Animals in Teaching and Research at the University
of Hong Kong (Approval Reference No. CULATR 1968-09). For
isolation of mouse hepatocytes, livers were minced and digested
with type IV collagenase (Sigma-Aldrich, St. Louis, MO). After
filtering and lysis of red blood cells, cells were counted for
immunofluorescence staining and flow cytometric analysis (FACS-
Calibur, BD Biosciences, San Jose, CA). Cells isolated from
embryonic livers were stained with anti-AFP antibody (R&D
systems, Minneapolis, MN) and anti-albumin antibody (R&D
systems) to distinguish hepatocytes for subsequent characterization
of GEP-expressing cells.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed paraf-
fin-embedded sections with Dako Envision Plus System (Dako,
Carpinteria, CA) following the manufacturer’s instruction with
modifications as described [18,19].
Immunofluorescence staining and flow cytometric
analysis
For expression of GEP, ABCB5, b-catenin, Oct4, Sox2,Nanog
and DLK1, cells were permeabilized with ice-cold 0.1% saponin
and then incubated with FITC-conjugated mouse anti-human
GEP (described previously [20]), unconjugated goat anti-human
ABCB5 (Everest Biotech Ltd, Oxfordshire, UK), Alexa Fluor 647-
conjugated mouse anti-human b-catenin, PerCP-Cy5.5-conjugat-
ed mouse anti-human Oct4, Alexa Fluor 647-conjugated mouse
anti-Sox2, PE-conjugated mouse anti-human Nanog (BD Biosci-
ences), unconjugated rat anti-DLK-1 (MBL International, Wo-
burn, MA), or equal amount of corresponding isotype control
antibodies. For ABCB5 and DLK1, cells were incubated with
NorthernLights (NL) 557-conjugated donkey anti-goat IgG
secondary antibody or NL637-conjugated goat anti-Rat IgG
secondary antibody, respectively, prior to staining with anti-GEP
antibody. For CD133 and EpCAM surface expression, cells were
stained with APC-conjugated mouse anti-human CD133 (Miltenyi
Biotec, Bergisch Gladbach, Germany), APC-conjugated mouse
anti-human EpCAM (BD Biosciences) or equal amount of
corresponding isotype control antibodies, prior to permeabiliza-
tion and staining with anti-GEP antibody.
Cell sorting
Isolation of GEP- and/or ABCB5-expressing cells was per-
formed by magnetic activated cell sorting (Miltenyi Biotec)
Oncofetal Protein and Hepatic Cancer Stem Cells
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according to manufacturer’s instructions. Briefly, cells were labeled
with FITC-conjugated mouse anti-human GEP (previously
described [20]) or biotin-conjugated rabbit anti-human ABCB5
(Rockland, Gilbertsville, PA) antibody, and then incubated with
anti-FITC or anti-biotin magnetic microbeads (Miltenyi Biotec),
followed by magnetic separation. Note that cells were sorted based
on the surface expression of GEP and ABCB5, but not on their
intracellular expression, because permeabilization was not feasible
to keep the cells viable for subsequent functional assays. After cell
isolation, 2 million of each sorted population were collected to
assess the cell viability by trypan blue staining and purity by flow
cytometry using mouse anti-human GEP (R&D systems) or goat
anti-human ABCB5 (Everest Biotech) antibody recognizing
epitopes different from those antibodies used for cell sorting. Cells
were then stained with PE-conjugated rabbit anti-mouse or
NL557-conjugated donkey anti-goat IgG secondary antibody for
GEP or ABCB5, respectively. For the evaluation of cell purity by
flow cytometry, sorted cells were permeabilised prior to staining so
that the total GEP and ABCB5 expression of the sorted
populations could be determined. Post-sorting analysis typically
indicated purities of .80% with minimal cell death (,10%).
Doxorubicin accumulation and apoptosis
Cells were incubated with or without 0.5 mg/ml doxorubicin for
24 hr. Intracellular doxorubicin accumulation was analyzed by
flow cytometry at FL2 spectrum; while cell apoptosis was
determined by Annexin V-FITC (FL1) and propidium iodide
(PI) (FL2) staining and flow cytometric analysis.
Colony formation assay
Freshly isolated cells were seeded at a density of 1000 cells/well
and allowed to grow for 10 days. Colony formation was assessed
by a colorimetric assay using crystal violet (Sigma Aldrich).
In vivo tumorigenicity experiments
BALB/c athymic nude mice of 5 weeks old were used to test the
in vivo tumorigenic potential of the cells. The study protocol was
approved by the Committee on the Use of Live Animals in
Teaching and Research at the University of Hong Kong. Various
numbers of cells were inoculated subcutaneously at the dorsal
region of the trunk of each animal. Mice were sacrificed between 8
and 16 weeks post-injection, at which tumors were harvested for
further examination. Those mice injected with HCC cells but with
no sign of tumor burden were generally terminated 5 months after
cell injection.
Statistical Analyzes
All data were expressed as mean values 6 standard deviation
(SD) from at least three independent experiments. Differences
between groups were assessed by the Student’s t test. A probability
Figure 1. GEP expression in mouse and human livers. (A) Immunohistochemical analysis showing GEP protein in fetal livers of mouse
(embryonic day 17.5) and human (10 weeks 6 days), but not in adult livers (Magnification6400). (B) Flow cytometric analyzes demonstrating the
expression of GEP and hepatic stem cell markers in mouse embryonic hepatocytes. The co-expression of GEP and hepatic stem cell markers CD133,
EpCAM, DLK1 and b-catenin were performed by quadruple-color flow cytometry, gating on the AFP+ and/or albumin+ hepatocytes of embryonic
livers. Cells co-expressing the respective markers were shown in the upper right quadrant of dot plots. Data are expressed as mean percentage of
cells+SD.
doi:10.1371/journal.pone.0028246.g001
Table 1. GEP regulates stem cell marker expression in liver cancer cell line Hep3B.
Hep3B parental GEP Overexpression (FL) GEP Suppression (sh)
GEP+ (%) 66.862.2 85.761.8 ** 20.162.9 ***
b-catenin+ (%) 18.361.2 40.561.5 *** 11.563.1 *
GEP+b-catenin+ (%) 16.861.9 37.561.3 *** 10.861.5 **
Oct4+ (%) 7.960.8 11.161.3 ** 2.460.3 **
GEP+Oct4+ (%) 7.460.7 10.360.9 *** 2.360.4 **
Nanog+ (%) 3.860.6 3.960.1 0.060.0 **
GEP+Nanog+ (%) 3.860.2 3.860.2 0.060.0 ***
Sox2+ (%) 1.360.3 5.060.2 *** 0.460.1 *
GEP+Sox2+ (%) 1.160.1 4.560.1 *** 0.260.2 **
CD133+ (%) 94.960.9 96.261.8 94.863.0
GEP+CD133+ (%) 66.162.3 75.460.2 * 19.462.9 ***
EpCAM+ (%) 95.660.6 96.461.7 95.260.4
GEP+EpCAM+ (%) 63.661.7 75.362.3 *** 19.962.3 ***
ABCB5+ (%) 27.863.8 72.964.5 *** 4.761.9 **
GEP+ABCB5+ (%) 27.363.4 63.765.3 *** 4.461.7 **
GEP overexpression increased, while GEP suppression decreased the expression of b-catenin, Oct4, Nanog, Sox2 and ABCB5, but not CD133 and EpCAM.
Cells were dually stained for GEP and stem cell markers. Protein expression of GEP, b-catenin, Oct4, Nanog, Sox2 and ABCB5 was detected by intracellular staining, while
that of CD133 and EpCAM was assessed by surface staining, and was then analyzed by flow cytometry. Data are expressed as mean percentage of positive cells 6 SD
from three independent experiments.
*P,0.05,
**P,0.01,
***P,0.001 when compared with Hep3B control.
doi:10.1371/journal.pone.0028246.t001
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(p),0.05 was considered significantly different. All analyzes were
performed using the statistical software GraphPad Prism for
Windows, Version 3.00 (GraphPad Software, CA, USA).
Results
GEP is a hepatic oncofetal protein
Previously, GEP mRNA was reported in the embryonic mouse
liver [13], but whether GEP translates into protein and its time of
switch-on/-off during liver development remains unknown. Since
fetal liver has plenty of hematopoietic stem cells in addition to fetal
hepatocytes, we need to identify the cell type(s) expressing GEP.
Here, we described for the first time the protein expression pattern
of GEP in human and mouse livers. By immunohistochemical
staining, GEP protein was detected in mouse and human fetal
livers, while adult livers were devoid of GEP-expressing hepato-
cytes (Figure 1A).
In mouse model, in order to distinguish GEP expression
specifically in hepatocytes, analysis of GEP level was performed by
triple-color flow cytometry, gating on AFP+ and/or albumin+ for
hepatocytes at all developmental stage. Inclusion of AFP+ and/or
albumin+ cells in all developmental stages would better reflect the
hepatocyte population in the liver because the proportion of AFP+
cells and albumin+ cells were different in embryonic, neonatal and
adult livers (Figure S1). GEP expression increased gradually from
embryonic day E11.5 (14.8%+6.9%) to E17.5 (30.8+9.2%).
Immediately after birth, GEP level decreased abruptly from day
1 (4.4+1.5%) to day7 (1.2+0.4%), and became almost undetectable
in adult mouse livers (0.9+0.4%) (Figure S1). Together with our
previous findings that GEP expressed in the majority of HCC
specimens, but not in the adjacent non-tumor liver tissues [18,19],
we confirmed that GEP was a hepatic oncofetal protein.
To characterize the stem cell signature of GEP+ fetal
hepatocytes, we examined the co-expression of GEP and several
hepatic stem cell or stem cell-related markers including CD133,
EpCAM, DLK1 and b-catenin [21,22,23,24] in the embryonic
livers (Figure 1B). Hepatoblasts would have serial changes along
developmental stages and give rise to hepatocytes and cholangio-
cytes. At embryonic day 11.5 (E11.5), expressions of CD133,
EpCAM, DLK1 and b-catenin were high in the hepatoblasts and
the majority of GEP-positive cells co-expressed all these hepatic
stem cell markers. At E13.5, expressions of CD133 and EpCAM
started to decline and most of the CD133+ or EpCAM+ cells
were observed to co-express GEP. For DLK1 and b-catenin, their
expression levels remained high at E13.5 and the majority of
GEP-expressing cells were also positive for both markers. At
E17.5, the expressions of CD133, EpCAM, DLK1 and b-catenin
decreased to low levels, while GEP expression reached the peak
at this stage. The discrepancy of expression trends between GEP
and these stem cell markers could be attributed to the growth
factor properties of GEP. While further investigation is needed to
elucidate the mechanism underlying the expression pattern of
GEP, the co-expression of GEP with these hepatic stem cell or
stem cell-related markers suggests a stem cell phenotype of GEP-
expressing cells.
The GEP expression in the mouse hepatocytes was investigated
by our home-made anti-GEP antibody A23. The specificity of A23
was examined by western blot (Figure S2) and the result showed
that it could recognize the mouse GEP as single band from the
mouse embryonic liver protein extract. Moreover, the GEP
expression pattern as shown in the western blot was consistent
with flow cytometry data in that GEP protein level increased from
E11.5 and E13.5 to E17.5, providing consistent data to reflect the
GEP expression in the embryonic livers.
Phenotypic characterization of GEP-expressing cells in
HCC
To better characterize if the GEP-expressing cells had the stem
cell properties in HCC, we examined the co-expression of GEP
and a panel of stem cell markers using flow cytometry in human
HCC cell lines Hep3B and Huh7. Markers examined include
hematopoietic precursor cell surface markers CD31, CD34,
CD117, hepatic precursor cell surface marker CD123, stem cell
surface markers CD24, CD29, hepatic CSC surface markers
CD44, CD90, CD133, EpCAM, ES cell-related signaling
molecules b-catenin, Oct4, Nanog and Sox2, ABC drug
transporters ABCC1 and ABCB5. Note that ABC drug trans-
porters were also included because both normal and cancer stem
cells expressed higher level of ABC drug transporters, contributing
to greater resistance to chemotherapeutic agents than differenti-
ated cells [4,21]. Among the markers being investigated, GEP+
cells were shown to preferentially co-express with b-catenin, Oct4,
Nanog, Sox2, CD133 and EpCAM when compared with GEP-
cells in both HCC cell lines Hep3B (Figure S3) and Huh7 (Figure
S4). Our findings therefore suggested a stem cell feature of GEP-
expressing cells in the both embryonic and cancerous liver cells.
GEP regulates expression of stem cell markers
We modulated the GEP expression levels in Hep3B cells by
transfection approach and investigated if the protein levels of the
stem cell markers would be altered. Results showed that up-
regulation of GEP level enhanced, while suppression of GEP level
decreased the expression of b-catenin, Oct4, Nanog, Sox2 and
ABCB5 (Table 1). Modulation on GEP levels did not changed the
expression of hepatic stem cell surface markers CD133 and
EpCAM. The reason might be due to the fact that the majority of
Hep3B cells were positive for CD133 and EpCAM (greater than
95%), thus change of one molecule (e.g. GEP) might not be able to
shift the population. While GEP has been previously reported by
our group to regulate ABCB5 to mediate chemoresistance in HCC
cells [25], the positive correlation between GEP and b-catenin,
Oct4, Sox2 and Nanog suggested that GEP might regulate the
expression of these ES cell-related signaling molecules to maintain
the pluripotency of stem cells.
To further validate the regulatory role of GEP on the expression
of these signaling molecules, GEP blockage by anti-GEP
Table 2. GEP blockage by anti-GEP antibodies suppresses the
expression of ES cell-related signaling molecules and ABCB5.
CTL mIgG A23
GEP+ (%) 70.363.6 67.361.1 37.766.7 *
b-catenin+ (%) 15.462.6 16.461.4 5.260.3 *
Oct4+ (%) 7.260.7 7.561.3 2.060.5 *
Nanog+ (%) 3.760.3 3.560.4 2.060.2 **
Sox2+ (%) 1.360.3 1.360.4 0.360.1 *
ABCB5+ (%) 31.361.6 28.161.1 11.662.9 *
Hep3B cells were treated with anti-GEP monoclonal antibody (A23), mouse IgG
isotype antibody (mIgG) (antibodies at 50 mg/ml) or without antibody (control,
CTL) for 24 h. Protein expression of GEP, b-catenin, Oct4, Nanog, Sox2 and
ABCB5 was measured by intracellular staining and analyzed by flow cytometry.
Data are expressed as mean percentage of positive cells 6 SD from three
independent experiments.
*P,0.05,
**P,0.01,
***P,0.001 when compared with Hep3B control.
doi:10.1371/journal.pone.0028246.t002
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monoclonal antibody A23 was performed in Hep3B cells (Table 2).
A23 was found to significantly reduce endogenous GEP levels in
Hep3B cells. GEP blockage also significantly suppressed the
expression of b-catenin, Oct4, Nanog and Sox2, thereby
confirming the regulatory role of GEP on the expression of these
stem cell-related signalling molecules.
GEP-expressing cells possess CSC properties in vitro
To better characterize the stem cell properties of GEP-
expressing cells, GEPhigh and GEPlow subpopulations were isolated
from human liver cancer cell lines Hep3B, HepG2 and Huh7, and
examined for their expression of stem cell markers using flow
cytometry. Cells were sorted based on the surface expression of
GEP, but not on its intracellular expression, because permeabi-
lization was not feasible to keep the cells viable for subsequent
functional assays. After cell isolation, 2 million of each sorted
population was collected to assess the cell viability by trypan blue
staining and purity by flow cytometry using a different anti-GEP
antibody that recognized distinct epitopes from those antibodies
used for cell sorting. The purity of the GEPhigh and GEPlow
subpopulations were about 80% to 90%, respectively, as revealed
by post-sorting analysis (Figure 2A). GEPhigh cells were found to
express higher levels of ES cells-related signaling molecules b-
catenin, Oct4, Nanog, Sox2 and ABC drug transporter ABCB5
than GEPlow counterparts in the three HCC cell lines (Figure 2B).
For hepatic CSC surface marker CD133, higher surface
expression in GEPhigh cells than GEPlow counterpart was found
in HepG2 and Huh7, but not Hep3B, which was probably due to
the extremely high level of CD133 (.95%) constitutively
expressed in the Hep3B cells (data not shown). For EpCAM,
higher surface expression was observed in GEPhigh than GEPlow
populations in Huh7, but not Hep3B and HepG2, in which
majority of cells (.95%) were found to express EpCAM. The data
is therefore consistent with the previous findings that GEP-
expressing cells associated with stem cell marker expressions
compared with the GEP negative cells.
To determine whether GEP-expressing cells were enriched for
CSCs, we compared the tumorigenic potential and stem cell
properties of GEPhigh cells with their counterparts in vitro in Hep3B
and HepG2 cells, which represent high and low GEP-expressing
cell lines, respectively. Clonogenicity of the cells was assessed by
colony formation assay. GEPhigh Hep3B cells were able to form
significantly more colonies compared with the GEPlow cells and
the unsorted control. Similar observation was shown with an
independent liver cancer cell HepG2 (Figure 2C).
To examine the role of GEP in chemoresistance, cells were
incubated with doxorubicin and assessed for intracellular drug
accumulation and cell apoptosis. GEPhigh subpopulations, in both
Hep3B and HepG2 cells, demonstrated significantly lower
doxorubicin uptake (Figure 2D) and cell apoptosis (Figure 2E)
when compared with unsorted control; while GEPlow subpopula-
tions showed increased doxorubicin uptake and cell apoptosis
when compared with unsorted populations.
GEPhighABCB5+ cells demonstrate higher colony
formation ability and chemoresistance
According to CSC hypothesis, CSCs represent only a rare
population of the tumor [4]. This implies that GEPhigh
subpopulation is still heterogeneous, and possibly consists of
subsets with differential tumorigenic potentials. Therefore, we
sought to further dissect the GEPhigh population by additional co-
expressing marker.
In Hep3B cells, the majority of ABCB5+ cells expressed GEP,
but only a subset of GEP+ cells were ABCB5+ (Figure 3A, left
panel). In addition, we have shown recently that ABCB5 regulated
hepatic cancer stem cell markers CD133 and EpCAM [21]. We
therefore hypothesized that GEP in combination with ABCB5
might define more accurately the hepatic CSC population.
We isolated GEPhighABCB5+, GEPhighABCB52 and GEPlow
ABCB52 cells from Hep3B. Cells were sorted based on the
surface expression of GEP and ABCB5, but not on their
intracellular expression, because permeabilization was not feasible
to keep the cells viable for subsequent functional assays. After cell
isolation, sorted subpopulations were assessed for cell viability by
trypan blue staining and purity by flow cytometry using different
anti-GEP or anti-ABCB5 antibodies that recognized distinct
epitopes from those antibodies used for cell sorting. At least 80%
purity was obtained in each subpopulation (Figure 3A) and their
tumorigenic potentials were examined both in vitro and in vivo.
GEPhighABCB5+ cells demonstrated induction of the largest
number of colonies, while the GEPhighABCB52 cells showed
intermediate ability to form colonies but still significantly higher
than the unsorted control. Importantly, GEPlowABCB52 subpop-
ulation was almost unable to form colonies (Figure 3B).
Upon exposure to doxorubicin, GEPhighABCB5+ cells demon-
strated significantly lower level of doxorubicin uptake and cell
apoptosis when compared with GEPhighABCB52 cells, and
unsorted control. On the contrary, GEPlowABCB52 cells were
highly sensitive to doxorubicin in terms of drug accumulation and
cell apoptosis (Figure 3C and D).
GEPhighABCB5+ cells are more tumorigenic in vivo
Tumor development experiments using GEPhighABCB5+ and
GEPlowABCB52 subpopulations isolated from Hep3B cells were
performed in immunocompromised nude mice. All mice injected
with GEPhighABCB5+ cells developed tumors. Mice injected with
16106 double positive cells formed tumors within 2 to 4 weeks
after inoculation. On the contrary, only 2/10 mice injected with
GEPlowABCB52 cells generated relatively small tumors and
required longer latency (12 weeks) (Figure 4A and B).
To demonstrate the in vivo self-renewal ability of the cells,
xenografts growing from the initial inoculation were serially
Figure 2. GEP-expressing cells isolated from liver cancer cell lines possess higher tumorigenic potential in vitro. (A) GEP expression in
unsorted Hep3B, HepG2 and Huh7 cells, and the freshly isolated GEPhigh, and GEPlow subpopulations after cell sorting. Cells were sorted based on
surface expression of GEP, but not on its intracellular expression, in order to keep the cells viable for subsequent functional assays. After cell isolation,
2 million of each sorted population was collected to assess the cell viability by trypan blue staining and the purity of the sorted subpopulations by
flow cytometry using a different anti-GEP antibody (recognizing distinct epitopes compared to the antibodies used for cell sorting). Data are
expressed as mean percentage of GEP+ cells 6 SD. (B) Protein expression levels of stem cell markers b-catenin, Oct4, Nanog, Sox2 and ABCB5 in the
sorted subpopulations were measured by intracellular staining and flow cytometric analysis. Data are expressed as mean percentage of positive cells
6 SD. *P,0.05, **P,0.01, *** P,0.001 when compared with GEPlow cells. (C) Colony formation efficiencies of GEP
high subpopulations were higher
than their respective GEPlow and unsorted Hep3B and HepG2 cells. (D, E) After exposure to doxorubicin (0.5 mg/ml for 24 h), GEP
high subpopulations
retained significantly less doxorubicin and fewer cell apoptosis than GEPlow and unsorted Hep3B and HepG2 cells. *P,0.05, **P,0.01, *** P,0.001
when compared with unsorted controls.
doi:10.1371/journal.pone.0028246.g002
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transplanted. Serial transplantation of xenografts derived from
GEPhighABCB5+, but not GEPlowABCB52 subpopulation, gen-
erated tumor nodules in the second and subsequently the third
passage in nude mice (Figure 4C).
We then characterized the xenograft tumors formed by
GEPhighABCB5+ cells by flow cytometry, and these cells revealed
low levels of GEP (8.365.2%) and ABCB5 (6.665.3%). The
phenomenon that transplantation of GEPhighABCB5+ cells
resulted in a heterogeneous populations consisting of GEP and
ABCB5 positive and negative cells suggested that tumor hierarchy
existed, in which the GEP+ and ABCB5+ cells were able to self-
renew and differentiate, generating their positive and negative
counterparts in the tumor mass (Figure S5). To validate the self-
renewal ability of GEP and ABCB5 expressing cells, we performed
in vitro short-term passages of cells derived from the GEPhigh-
ABCB5+ xenograft. Over the 3 week culture period, asymmetric
division occurred in which GEP+ and ABCB5+ fractions increased
until the levels returned to those of the unsorted Hep3B cells
(Figure S5).
The above data was therefore consistent with the in vitro findings
that co-expression of GEP and ABCB5 could enrich a subpop-
ulation with higher tumorigenic potential than their counterparts.
Phenotypic characterization of GEP-expressing cells in
HCC clinical specimens
To confirm the stem cell phenotype of GEP-expressing cells in
clinical settings, GEP was co-stained with the aforementioned stem
cell markers in six HCC clinical specimens. Liver tissues were
digested into single cell suspension, and assessed for the expression
of albumin, GEP and the stem cell markers by flow cytometry.
Consistent with our previous findings, GEP protein expression was
observed in HCC (4.962.5%), but not in adjacent non-tumor liver
tissues (Figure 5A). Co-expression of GEP and stem cell markers
was examined by triple-color flow cytometry, gating on the
Figure 3. Co-expression of GEP and ABCB5 further enriches a hepatic CSC subpopulation. (A) GEP and ABCB5 expression in unsorted
Hep3B cells, and the freshly isolated GEPhighABCB5+, GEPhighABCB52 and GEPlowABCB52 subpopulations. Cells were sorted based on surface
expression of GEP and ABCB5. After cell isolation, 2 million of each sorted subpopulation was collected to assess purity by flow cytometry using
different anti-GEP and anti-ABCB5 antibodies that recognized epitopes distinct from those of the antibodies used for cell sorting. Note that most
ABCB5+ cells were also GEP+, thus there was no GEPlowABCB5+ cells (left panel). Mean percentage of cells6 SD is shown in each quadrant. (B) Colony
formation efficiencies of GEPhighABCB5+ subpopulation were higher than GEPhighABCB52, GEPlowABCB52 and unsorted cells. (C, D) After exposure to
doxorubicin (0.5 mg/ml for 24 h), GEPhighABCB5+ cells retained significantly less doxorubicin and fewer cell apoptosis than the other subpopulations.
*P,0.05, **P,0.01 when compared with unsorted controls; # P,0.05, # # P,0.01, # # # P,0.001 between groups denoted by horizontal lines.
doi:10.1371/journal.pone.0028246.g003
Figure 4. GEPhighABCB5+ Hep3B cells possess enhanced tumorigenic potential in vivo. (A) Nude mice injected subcutaneously with
GEPhighABCB5+ and GEPlowABCB52 cells after 8 weeks. The right panel shows the subcutaneous tumors derived from 2.56105 GEPhighABCB5+ and
16106 GEPlowABCB52 cells at week 16. (B) Tumorigenicity of GEP
highABCB5+ and GEPlowABCB52 cells. (C) Serial transplantation of primary tumors
generated from GEPhighABCB5+ and GEPlowABCB52 cells.
doi:10.1371/journal.pone.0028246.g004
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Figure 5. Phenotypic characterization of GEP-expressing cells in HCC clinical specimens. Liver tissues obtained from HCC patients were
digested into single cell suspension, and assessed for the expression of albumin, GEP and stem cell markers. (A) Flow cytometric analyzes showing
GEP expression in HCC, but not in adjacent non-tumor liver tissues. GEP expression analysis was performed by dual-color flow cytometry, gating on
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albumin+ hepatocytes. ES cells-related signalling molecules
including b-catenin, Oct4, Nanog, Sox2 and hepatic CSC surface
marker CD133 was preferentially expressed in GEP+ population
(Figure 5B). EpCAM, it was found to express in the majority of
hepatocytes (63.8634.2%), and most, if not all GEP+ cells were
also positive for EpCAM. Most importantly, the majority of the
cells expressing ABCB5 were also positive for GEP staining, but
only a subset of GEP+ cells were ABCB5+. The result is therefore
consistent with our in vitro findings on the co-expression of GEP
and ABCB5, and provided further evidence that co-expression of
GEP and ABCB5 might define more accurately the hepatic CSC
population.
Discussion
Previously, our group reported the role of GEP in HCC growth
and tumorigenicty [19], regulation of chemoresistance [25], and
the potential to serve as therapeutic target [20]. However, its exact
biological role in human liver remains unknown. In this study, we
demonstrate that GEP is a hepatic oncofetal protein with the
properties of both primitive stem and cancer cells. The present
work is the first report showing the nature of GEP as oncofetal
protein in human and mouse livers, and also the first study
showing the CSC properties of GEP-expressing cells. Therefore,
GEP might be a promising candidate to pursue further for novel
therapeutic development for liver cancer.
Since tumorigenicity of CSCs is largely determined by their self-
renewal ability [26], differentiation of CSCs might therefore
suppress carcinogenesis. It is now believed that multiple dysreg-
ulated self-renewal pathways are functioning to maintain the CSC
subpopulations [27]. Our transfection studies demonstrated a
positive correlation between the expression of GEP and those of
stem cell signaling molecules including b-catenin, Oct4, Nanog
and Sox2, suggesting a regulatory role of GEP on these signaling
molecules. Dysregulation of the Wnt/b-catenin was found to result
in transformation of liver stem/progenitor cells, thereby implying
a role in self-renewal of hepatic stem cells [28]. Oct4, Nanog and
Sox2 are three core transcription factors regulating cellular
pluripotency and are known to suppress differentiation in ES cells
[29]. In this study, we showed that GEP blockage by anti-GEP
monoclonal antibody A23 could significantly suppress the
expression of these pluripotency-related signaling molecules. Our
group previously showed that phosphorylation of Akt were
reduced after A23 treatment in a dose-dependent manner [20].
PI3K/Akt plays crucial role in proliferation, survival, and
maintenance of pluripotency in ES cells [30,31], and these effects
were found to mediate through the phosphorylation of GSK3b,
leading to increased Wnt/b-catenin activity [32,33]. Recently, Lee
et al reported that Wnt and PI3K signals were required for the
expression of representative pluripotency marker genes such as
Oct4 and Sox2 [33]. Therefore, it is possible that GEP might
regulate the expression of the aforementioned pluripotency-related
signaling molecules via the activation of PI3K/Akt pathway,
although further investigations are needed to support this
hypothesis. While the underlying regulatory mechanism remains
to be elucidated, the data suggest that GEP not only define a CSC
subpopulation in HCC, but also functionally contribute to the
stemness of CSCs by regulating the related signalling molecules.
Targeting GEP by antibody A23 might therefore serve as a
potential therapeutic tool to ‘‘de-stem’’ the CSCs and ultimately
sensitize them to conventional therapies. Further efforts would be
made towards elucidating the molecular mechanism(s) underlying
the regulatory role GEP in maintaining pluripotency of CSCs.
Increasing evidence has shown that a single marker is
insufficient to define the real CSC population [34]. It is therefore
worthwhile to identify additional markers co-expressing with GEP
to better characterize the hepatic CSCs. Recently, we have
demonstrated a positive correlation between GEP and ABCB5
and also their roles in chemoresistance in HCC [25]. While
ABCB5+ cells were reported to define a CSC subpopulation in
melanoma [35], their tumorigenic potential in HCC remained
unknown. Here, we provide further evidence showing that GEP
and ABCB5 could define more specifically a hepatic CSC
population with greater tumorigenic potential and stem cell
properties than GEP alone. Since ABCB5 represents a potential
chemoresistance mechanism [36], GEPhighABCB5+ hepatic CSCs
might be responsible for both initiation and chemotherapeutic
refractoriness of HCC. Together with the regulatory role of GEP
in stem cell-related signalling molecules, targeting GEP and
ABCB5 might therefore represent novel therapeutic strategies to
the disease by interrupting both chemoresistance and pluripotency
in the CSCs.
GEPhighABCB5+ cells constitute about 4% of hepatocytes in
HCC clinical specimens (Figure 5). According to CSC hypothesis,
tumor-initiating ability specifically resides in a rare population of
cells within a tumor [4]. However, it is now believed that the
frequency of CSCs could vary dramatically within cancer of the
same type [35,37]. In fact, recent mathematical analyses indicated
that the CSC proportion should be higher in more aggressive
tumors [38]. Nevertheless, continued phenotypic studies of
GEPhighABCB5+ cells in HCC clinical specimens are needed to
more accurately determine the CSC frequency and to prove
enrichment, which might eventually allow correlation between
CSC frequency, tumor grade and clinical outcome. The current
study has a small sample size therefore with limited statistical
power to analyze for the clinicopathological characteristics.
Further validation in clinical settings is needed to confirm the
tumor-initiating ability of GEPhighABCB5+ subpopulation.
Supporting Information
Figure S1 GEP expression in mouse hepatocytes by flow
cytometry. Flow cytometric analyzes demonstrating GEP,
albumin and AFP expression in mouse livers. GEP expression in
(A) total cells isolated from mouse livers, (B) AFP+ and/or
albumin+ cells, (C) AFP+ cells, and (D) albumin+ cells was
performed by intracellular staining and single- or dual-color flow
cytometry. (E) AFP and (F) albumin expression in mouse livers at
different developmental stages were examined by flow cytometry.
(TIF)
Figure S2 Protein expression of GEP in mouse embry-
onic livers by Western blot using anti-GEP monoclonal
antibody A23. The anti-GEP monoclonal antibody A23
specifically recognized mouse GEP at about 75 kDa. GEP
expression was detected in mouse embryonic livers and increased
the albumin+ hepatocytes of liver specimens. (B) Co-expression of GEP and stem cell markers was performed by triple-color flow cytometry, gating on
the albumin+ hepatocytes of HCC specimens. Protein expression of GEP, b-catenin, Oct4, Nanog, Sox2 and ABCB5 was measured by intracellular
staining, while that of CD133 and EpCAM was assessed by surface staining. Cells co-expressing the respective markers were shown in the upper right
quadrant of dot plots. Data were presented as mean percentage of cells 6 SD.
doi:10.1371/journal.pone.0028246.g005
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from E11.5 to E17.5. b-actin expression was examined to ensure
equal loading of protein.
(TIF)
Figure S3 Phenotypic characterization of GEP-express-
ing cells in liver cancer cell line Hep3B. Flow cytometric
analyzes showing co-expression of GEP with stem cell markers b-
catenin, Oct4, Nanog, Sox2, CD133, EpCAM and ABCB5.
Protein expression of GEP, b-catenin, Oct4, Nanog, Sox2 and
ABCB5 was measured by intracellular staining, while that of
CD133 and EpCAM was assessed by surface staining. Cells co-
expressing the respective markers were shown in the upper right
quadrant of each scatter plot. Data are expressed as mean
percentage of cells 6 SD.
(TIF)
Figure S4 Phenotypic characterization of GEP-express-
ing cells in liver cancer cell line Huh7. Flow cytometric
analyzes showing co-expression of GEP with stem cell markers b-
catenin, Oct4, Nanog, Sox2, CD133, EpCAM and ABCB5.
Protein expression of GEP, b-catenin, Oct4, Nanog, Sox2 and
ABCB5 was measured by intracellular staining, while that of
CD133 and EpCAM was assessed by surface staining. Cells co-
expressing the respective markers were shown in the upper right
quadrant of each scatter plot. Data are expressed as mean
percentage of cells 6 SD.
(TIF)
Figure S5 In vitro self-renewal ability of GEP positive
and ABCB5 positive cells. Flow cytometric analyzes showing
the increasing GEP and ABCB5 expression in primary culture
established from GEPhighABCB5+ cells-induced xenograft tumors
over a 3-week culture period.
(TIF)
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